Xinmei Shen is a technology reporter at the Post. She covers a range of topics including content, entertainment, social media, and internet culture, with a particular focus on artificial intelligence, machine learning, and cryptocurrency. Xinmei's work has been featured in Newswav, MSN, South China Morning Post SCMP, and The Star Online.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Xinmei Shen's focus is primarily on cryptocurrency, blockchain, and technology within the local markets of China and Hong Kong. Her articles often cite government announcements and data, indicating a preference for official information or statistics to support her reporting.
Given Xinmei's emphasis on Chinese and Hong Kong markets, she may respond well to pitches from experts with in-depth knowledge of the regulatory landscape specific to these regions. Additionally, individuals who can provide insights into market trends backed by reliable data sources could be valuable for her articles.
Considering her coverage attributes and topics covered, professionals familiar with cryptocurrency regulations in China and Hong Kong or those with expertise in technology developments within these regions might find success when reaching out to Xinmei.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Xinmei Shen
The cryptocurrency is unlikely to climb back above US$100,000 this year as risks remain from interest rate rises to an escalation in Iran
By: Xinmei Shen
The cryptocurrency is unlikely to climb back above US$100,000 this year as risks remain from interest rate rises to an escalation in Iran.
By: Xinmei Shen
US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial
By: Xinmei Shen
Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation
By: Xinmei Shen
Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say
By: Xinmei Shen
Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say
By: Xinmei Shen
Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say.
By: Xinmei Shen
Net profit reached 2.46 billion yuan for the quarter, also above analyst estimates
By: Xinmei Shen
Net profit reached 2.46 billion yuan for the quarter, also above analyst estimates.
By: Xinmei Shen
Hansoh Pharmaceutical, Akeso and others tout positive results as Chinese research accounts for larger percentage of presentations.
